Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ cut its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,100 shares of the biopharmaceutical company’s stock after selling 15,527 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Halozyme Therapeutics were worth $1,541,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. GSA Capital Partners LLP purchased a new position in shares of Halozyme Therapeutics during the third quarter worth $217,000. CIBC Asset Management Inc acquired a new stake in Halozyme Therapeutics during the 3rd quarter worth about $211,000. Natixis Advisors LLC raised its stake in shares of Halozyme Therapeutics by 86.7% during the 3rd quarter. Natixis Advisors LLC now owns 121,560 shares of the biopharmaceutical company’s stock valued at $6,958,000 after buying an additional 56,461 shares during the last quarter. TrinityPoint Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $214,000. Finally, Quest Partners LLC boosted its stake in shares of Halozyme Therapeutics by 1,386.0% in the third quarter. Quest Partners LLC now owns 9,793 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 9,134 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Up 1.1 %

Shares of NASDAQ HALO opened at $62.95 on Tuesday. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The company’s 50-day simple moving average is $57.05 and its 200-day simple moving average is $54.63. The firm has a market cap of $7.75 billion, a price-to-earnings ratio of 18.35, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HALO. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Benchmark restated a “buy” rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $62.78.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.